{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Nasus Pharma Ltd. Ordinary Shares"},"Symbol":{"label":"Symbol","value":"NSRX"},"Address":{"label":"Address","value":"YIGAL ALON 65, TEL AVIV, 6744317, Israel"},"Phone":{"label":"Phone","value":""},"Industry":{"label":"Industry","value":null},"Sector":{"label":"Sector","value":null},"Region":{"label":"Region","value":null},"CompanyDescription":{"label":"Company Description","value":"Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions. Our mission is to offer better protection to patients during acute, severe and life-threatening medical conditions by an effective, user-friendly and immediately active powder-based intranasal technology, or PBI, specialized products. To help achieve this we are focused on developing NS002, an intranasal powder Epinephrine nasal spray for the treatment of type 1 severe allergies and anaphylaxis, or Intranasal Epinephrine, and we also have been developing NS001, an intranasal Naloxone powder nasal spray for the treatment of opioid overdose, or Intranasal Naloxone. We currently have no FDA approved products. Our products have been tested on relatively small patient populations thus far."},"CompanyUrl":{"label":"Company Url","value":null}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}